ANDA 76347, held by Epic Pharma. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 76347 (Tizanidine Hydrochloride), held by Epic Pharma, was first approved by FDA on Oct 11, 2002, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 11, 2002 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Jul 18, 2016 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 10, 2007 | Supplement 6Labeling | Approved | None posted |
| Mar 2, 2007 | Supplement 5Labeling | Approved | None posted |
| Jan 12, 2007 | Supplement 4Labeling | Approved | None posted |
| Oct 11, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters